Table 2.
Secondary outcome 1 (clinical deterioration) by predictors of interest and death∗.
| Predictors of interest | No clinical deterioration (N = 1614) | Clinical deterioration (N = 218) | Overall (N = 1832) | Difference t-test or chi-square, p value |
|
| ||||
| PE severity at presentation, N (%) | ||||
| High risk | 32 (2.0%) | 107 (49.1%) | 139 (7.6%) | <0.001 |
| Intermediate-high risk | 631 (39.1%) | 76 (34.9%) | 707 (38.6%) | |
| Intermediate-low risk | 944 (58.5%) | 33 (15.1%) | 977 (53.3%) | |
| Low risk | 7 (0.4%) | 2 (0.9%) | 9 (0.5%) | |
| Bleeding risk assessment, N (%) | ||||
| High | 203 (12.6%) | 45 (20.6%) | 248 (13.5%) | 0.006 |
| Moderate | 812 (50.3%) | 103 (47.2%) | 915 (49.9%) | |
| Low | 599 (37.1%) | 70 (32.1%) | 669 (36.5%) | |
|
| ||||
| PE severity and bleeding risk profile, N (%) | No clinical deterioration (N = 1614) | Clinical deterioration (N = 218) | Overall (N = 1832) | |
|
| ||||
| High PE/high bleeding risk | 15 (0.9%) | 19 (8.7%) | 34 (1.8%) | <0.001 |
| High PE/moderate bleeding risk | 12 (0.7%) | 50 (22.9%) | 62 (3.4%) | |
| High PE/low bleeding risk | 5 (0.3%) | 38 (17.4%) | 43 (2.3%) | |
| Intermediate-high PE/high bleeding risk | 93 (5.8%) | 20 (9.2%) | 113 (6.2%) | |
| Intermediate-high PE/moderate bleeding risk | 319 (19.8%) | 36 (16.5%) | 355 (19.4%) | |
| Intermediate-high PE/low bleeding risk | 219 (13.6%) | 20 (9.2%) | 239 (13.0%) | |
| Intermediate-low PE/high bleeding risk | 95 (5.9%) | 6 (2.8%) | 101 (5.5%) | |
| Intermediate-low PE/moderate bleeding risk | 478 (29.6%) | 16 (7.3%) | 494 (27.0%) | |
| Intermediate-low PE/low bleeding risk | 378 (23.4%) | 13 (6.0%) | 391 (21.3%) | |
| Outcome | ||||
| Death | 10 (0.6%) | 84 (38.5%) | 94 (5.1%) | <0.001 |
∗ The percentages within each cell were calculated using the N in the column header for that cell.